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Abstract
Background: China’s national tuberculosis control program (NTP) provides free, first-line anti-tuberculosis (TB) drugs
to pulmonary TB patients. This treatment regimen follows the World Health Organization’s (WHO) guideline. The
objective of this paper is to evaluate the current status of anti-TB drug use for newly diagnosed pulmonary TB
inpatients treated in prefecture- and county-level designated hospitals.
Methods: Three prefecture-level hospitals and nine county-level hospitals were selected for the study. All newly
diagnosed pulmonary TB inpatient medical records from 2012 were reviewed and doubly examined by two national
senior physicians. The rational use of anti-TB drugs was evaluated based on criteria in line with WHO’s guideline.
Results: Of the 2,060 total treatment regimens for TB, 53.1 % were found to be rational (1093/2060). The percentages
in prefecture-level and county-level hospitals were 50.3 % (761/1513) and 60.7 % (332/547), respectively. The difference
between the two levels of hospitals was statistically significant (Chi-square value = 17.44, P < 0.01). The percentages of
rational treatment regimens for first-time hospitalizations and for two or more hospitalizations were 59.5 % (983/1653)
and 27.0 % (110/407), respectively, with a statistically significant difference (Chi-square value = 138.00, P < 0.01). The
overall use of second-line drugs (SLD) was 54.9 % (1131/2060). The percentages for prefecture-level and county-level
hospitals were 50.6 % (766/1513) and 66.7 % (365/547), respectively. A statistically significant difference was found
(Chi-square value = 42.06, P < 0.01). The use of SLD for inpatients hospitalized once and inpatients hospitalized twice or
more was 58.4 % (966/1653) and 40.5 % (165/407), respectively, with a statistically significant difference (Chi-square
value = 42.26, P < 0.01).
Conclusions: Half of inpatients might be treated with irrational regimens, and the use of SLD was more appropriately
dispensed in city-level hospitals than in county-level hospitals. Trainings and guidelines for health personnel,
supervision led by health authorities and increased investment to designated hospitals may help to improve the
rational use of anti-TB drugs.
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Background
According to the World Health Organization (WHO) esti-
mate, China has one of the largest numbers of tubercu-
losis (TB) patients with multi-drug resistant tuberculosis
(MDR-TB) in the world [1]. A major contributing factor
to the rise of MDR-TB is non-adherence to or irrational
TB treatment regimens [2]. Tuberculosis is not only a
major public health issue in China, but is a social problem
as well. With the second highest TB burden in the world,
China accounted for 16 % of all TB cases that were noti-
fied in 2012 [1]. In the past two decades, China has made
good progress in TB control via a vertical Center of Dis-
ease Control and Prevention (CDC) system. It has also
played an important role in global TB control through the
implementation of the Directly Observed Treatment,
Short-course (DOTS) strategy and through strengthening
TB case treatment and management, as evidenced by the
national prevalence survey results conducted in 1990 and
2010, which confirmed that China achieved a 65 % decline
in the prevalence of smear-positive TB [3, 4]. However,
China is still facing a great challenge in advancing the re-
duction of TB morbidity and mortality and in effectively
controlling MDR-TB. This challenge is further compli-
cated by the current transition of responsibilities for TB
care and control from the CDC to designated hospitals
[5], so it is critical to understand the current status of ra-
tional TB drug use in hospitals. The integrated model,
where designated hospitals, often functioning as general
hospitals, provide TB care, aims to produce the best out-
comes of TB care and treatment. Studies showed that des-
ignated hospitals had the lowest rate of unnecessary
hospitalizations and placed the lowest financial burden on
uncomplicated TB patients [6].
At present, the national tuberculosis control program
(NTP) in China provides free, first-line anti-TB drugs
(FLD). All TB drug dispensaries, including designated hos-
pitals, are required to provide standard treatment regimens
for newly diagnosed TB patients. However, the irrational
use of anti-TB drugs is still a common occurrence in China
and globally [7, 8], which may lead to serious implications
for the quality and cost of services [9, 10]. In addition, ir-
rationally used anti-TB drugs may result in resistance to
TB and cause further transmission throughout the com-
munity [11]. There are several reasons why irrational use
of anti-TB drugs has occurred: ambiguity in clinical guide-
lines, insufficient diagnostic modalities, and poor docu-
mentation concerning referred patients, etc. [12].
Although there are published studies describing anti-
TB drug use in China [13–18], they mainly focus on
either the use of FLD or second-line anti-TB drugs
(SLD), independently. To determine the situation of
anti-TB drug use in China, including both FLD and
SLD, we conducted a retrospective study in the China
Ministry of Health (MOH)-Gates Foundation TB project
pilot cities, which included Zhengjiang City, Jiangsu
Province in the east, Yichang City, Hubei Province in
central China, and Hanzhong City, Shaanxi Province in
the west, and selected TB inpatients as a sample in order
to acquire reliable data and information.
Methods
Study design
The goal of the China MOH-Gates Foundation TB pro-
ject was to develop comprehensive models for TB con-
trol and evaluate their feasibility and effectiveness. To
better design the intervention measures and collect
baseline data for future impact assessments, a baseline
survey, consisting of anti-TB drug use, among other
questions, was conducted.
The three prefecture-level hospitals in Zhenjiang,
Yichang and Hanzhong were all upper second-class hospi-
tals that specialized in infectious diseases. These hospitals
were designated by local health authorities to diagnose
and treat MDR-TB patients living in each respective city
and nearby counties before 2010. Three county-level des-
ignated hospitals were randomly selected from each city
based on GDP per capita (i.e., low, middle and high levels),
and in total nine county-level hospitals were surveyed.
Seven of the nine county-level hospitals were upper
second-class general hospitals and were designated for the
diagnosis and treatment of TB patients before 2013. The
other two hospitals were middle second-class general
hospitals and were designated only for the diagnosis
and treatment of TB inpatients, while the local CDC
was responsible for the diagnosis and treatment of
TB outpatients.
Data sources and collection
Information on TB inpatients were stored via medical
records in all hospitals, including diagnosis results, treat-
ment regimens, use of auxiliary drugs and clinical exam-
inations. In total, 4,076 medical records with a discharge
diagnosis of pulmonary TB and a discharge date in 2012
were imported from the hospital information system,
and 482 records were excluded due to drug-resistance,
HIV-positive status and/or obsolete TB. The other The
remaining 3,594 pulmonary TB inpatient medical re-
cords were then examined independently by two chest
physicians. First, one physician recorded treatment regi-
mens prescribed for and used by each patient during
their hospitalization, the dates of hospital admission and
discharge, and personal information (e.g., sex, age, etc.)
using a designated form. According to the study design,
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we did not collect information on the use of auxiliary drugs
and clinical examinations. Afterwards, the second phys-
ician checked the records again to ensure that the informa-
tion was recorded correctly. Inpatients who were treated
for other diseases were excluded from the study, as those
with co-morbidities often did not begin TB treatment until
other health problems were controlled or until they re-
ceived complex treatments to address co-morbidities.
While examining the medical records, in-depth inter-
views with the deputy deans of the hospitals and focus
group interviews with TB physicians were conducted by
trained interviewers to understand the behaviors of the
deputy deans and TB physicians.
Data management and analysis
In China, all diagnosed pulmonary TB cases are required
to be reported and recorded in the national electronic
TB Information Management System (TBIMS), includ-
ing information regarding demographics, diagnosis date
and results, treatment history, etc. We acquired the pa-
tients’ information from the TBIMS and linked it with
the hospitalization medical record database. We only in-
cluded new TB patients (i.e., those never treated for TB),
and excluded retreatment cases, most of whom were
chronic TB patients. Finally, 1,653 cases with 2,060 med-
ical records were analyzed.
The rational use of treatment regimens was then ana-
lyzed and assessed based on treatment guidelines for the
initial phase (i.e., the first two months) and the continu-
ation phase (i.e., the last four months). The rationality of
treatment regimens was determined by how strictly treat-
ments followed the WHO guidelines, which was 2HRZE/
4HR for new TB patients [19]. Deviations from the WHO
guidelines were discussed with a third chest physician
from the study hospital to analyze the reasons for modify-
ing the inpatient’s TB treatment regimen. 2HRE/4HR was
regarded as rational if the TB inpatients were over 65 years
old, and 2HRZES/6HRE and 3HRZE/6HRE were rational
if the TB inpatients were only resistant to isoniazid. In the
case of side effects, 2HRZE/4HR was rational if rifampicin
was replaced with rifapentine and/or if pyrazinamide was
replaced with kanamycin, levofloxacin or other SLDs.
Ethics Review
The study protocol was approved by the China CDC in-
stitutional review board, as the study only used routine
data and did not involve any human participation.
Therefore, the application for waiving the informed con-
sent was accepted by the institutional review board.
Results
Demographics of the study population
There were 1,653 TB inpatients included in the study, of
which 70.7 % were male and 29.3 % female. Out of the
five age groups, TB cases in the 60 years old and over
group accounted for the largest percentage at 33.6 %,
while the 0–14 age group accounted for the smallest
percentage (0.7 %). In general, there was a negative rela-
tionship between the proportion of inpatients and age
group (Table 1).
Level of hospital and number of hospital admissions
Among all 1,653 TB inpatients, 1,150 cases (69.6 %)
were from prefecture-level hospitals, while 503 cases
(30.4 %) were from county-level hospitals. We found
that 85.0 % were hospitalized only once. At the
prefecture-level hospitals, 81.5 % of inpatient TB cases
were only hospitalized once, while the proportion was
93.5 % at the county-level hospitals. A statistically sig-
nificant difference was found between the two types of
hospitals (Chi-square value = 36.69, P < 0.01) (Table 2).
Rational use of treatment regimens
The overall rate of rational use of treatment regimens was
53.1 %. The percentages in prefecture-level and county-
level hospitals were 50.3 % and 60.7 %, respectively,
with a statistically significant difference (Chi-square
value = 17.44, P < 0.01). The rational use of treatment
regimens for first-time hospitalizations and for two or
more hospital admissions was 59.5 % and 27.0 %, re-
spectively. The difference was statistically significant
(Chi-square value = 138.00, P < 0.01), but the interpret-
ation was not clear. Prefecture-level (Chi-square value =
118.95, P < 0.01) and county-level hospitals showed similar
results (Chi-square value = 7.85, P < 0.01) (Table 3).
Use of SLD
The overall use of SLD for all study cases was 54.9 %.
The percentages in prefecture- and county-level hospi-
tals was 50.6 % and 66.7 %, respectively, with a signifi-
cant difference (Chi-square value = 42.06, P < 0.01). The
use of SLD for inpatients hospitalized once and inpa-
tients hospitalized twice or more was 58.4 % and 40.5 %,
respectively, with a significant difference (Chi-square
value = 42.26, P < 0.01). The prefecture-level hospitals
showed similar results; however, (Chi-square value =




n % n % n %
0- 7 0.6 5 1.0 12 0.7
15- 257 22.0 126 26.0 383 23.2
30- 191 16.3 93 19.2 284 17.2
45- 306 26.2 113 23.3 419 25.3
60- 408 34.9 147 30.4 555 33.6
Total 1169 100.0 484 100.0 1653 100.0
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30.39, P < 0.01) the county-level hospitals had a signifi-
cantly higher rate of SLD use (Chi-square value = 0.62,
P = 0.43) (Table 4).
Treatment regimen and SLD use
The use of SLD for inpatients treated with rational and ir-
rational regimens was 49.6 % and 50.4 %, respectively,
with a significant difference (Chi-square value = 12.03,
P < 0.01). Similar trends were observed at prefecture-
(Chi-square value = 50.76, P < 0.01) and county-level
hospitals (Chi-square value = 19.00, P < 0.01) (Table 5).
Discussion
This study showed that about half of the TB inpatients
were treated with irrational regimens and that half of
them were also treated with SLD. The treatment regi-
mens given to TB inpatients for first-time hospital ad-
missions were more rational than for those who were
hospitalized two or more times. This finding was evident
in both the prefecture- and county-level hospitals. Fur-
thermore, 15 % of TB inpatients were hospitalized twice
or more, and the percentage was higher in prefecture
hospitals than in county hospitals, which was not sur-
prising as the prefecture hospitals received more com-
plex and severe cases referred by the county hospitals.
Many factors may be associated with the irrational use
of TB treatment regimens and the overuse of SLD, espe-
cially in the county hospitals. First, the high deviation
from standard guidelines may be due to revenue gener-
ation. Perverse financial incentives given to hospitals
have likely been a main factor affecting the irrational use
of medicines in China [13, 20, 21]. Chinese hospitals are
not fully financed by public funds; thus, they need to
generate a substantial amount of revenue to cover their
operational costs. In this study, the government’s direct
investment to the prefecture hospitals in 2012 accounted
for about 12.8 % of total revenue, while the proportion
in the county hospitals was about 3.2 %. In addition, the
income levels of doctors and other health professionals
in Chinese hospitals are closely associated with the de-
gree of revenue generation. Chinese physician salaries
are often very low, supplemented by so-called bonus
payments that are linked to revenue generation. In order
to increase the level of revenue for hospitals and bonus
payments, physicians often admit more patients, overuse
unnecessary tests, and overprescribe medications, par-
ticularly expensive ones [22] since first-line anti-TB
drugs are paid for by government earmarked funds.
Thus, hospitals do not obtain any financial benefits from
the use of FLD. Therefore, it is not surprising to see that
doctors prefer to prescribe SLD, which can bring rev-
enue to the hospital and increase bonus payments for
themselves.
Table 2 TB inpatients by hospital level and hospital admission
Hospital
level
One hospital admission Hospital admissions >1 time Total
n % n %
Prefecture 937 81.5 213 18.5 1150
County 468 93.0 35 7.0 503
Total 1405 85.0 248 15.0 1653








N % N %
Prefecture 1st 669 58.2 % 481 41.8 % 1150
2nd − + 92 25.3 % 271 74.7 % 363
Sub-total 761 50.3 % 752 49.7 % 1513
County 1st 314 62.4 % 189 37.6 % 503
2nd- 18 40.9 % 26 59.1 % 44
Sub-total 332 60.7 % 215 39.3 % 547
Total 1st 983 59.5 % 670 40.5 % 1653
2nd- 110 27.0 % 297 73.0 % 407
Sub-total 1093 53.1 % 967 46.9 % 2060






Use of SLD Nonuse of SLD Total
n % n %
Prefecture 1st 628 54.6 % 522 45.4 % 1150
2nd- 138 38.0 % 225 62.0 % 363
Sub-total 766 50.6 % 747 49.4 % 1513
County 1st 338 67.2 % 165 32.8 % 503
2nd- 27 61.4 % 17 38.6 % 44
Sub-total 365 66.7 % 182 33.3 % 547
Total 1st 966 58.4 % 687 41.6 % 1653
2nd- 165 40.5 % 242 59.5 % 407
Sub-total 1131 54.9 % 929 45.1 % 2060





Rational regimen Irrational regimen Total
N % N %
Prefecture Yes 316 41.3 % 450 58.7 % 766
No 445 59.6 % 302 40.4 % 747
Sub-total 761 50.3 % 752 49.7 % 1513
County Yes 245 67.1 % 120 32.9 % 365
No 87 47.8 % 95 52.2 % 182
Sub-total 332 60.7 % 215 39.3 % 547
Total Yes 561 49.6 % 570 50.4 % 1131
No 532 57.3 % 397 42.7 % 929
Sub-total 1093 53.1 % 967 46.9 % 2060
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Second, quality assurance systems have not been well
implemented in most Chinese county general hospitals,
and it is difficult to supervise the doctors’ behaviors [23].
Although the CDC is still responsible for TB control
and prevention in China, the tasks of patient diagnosis
and treatment have now been shifted from the CDC to
the designated hospitals. The CDC, particularly at the
county level, lacks the authority and/or capacity to
monitor and supervise the TB services provided by the
hospitals. They are often in a weak position to point out
the irrationality of treatment regimens prescribed by the
hospitals, as most of the CDC public health doctors are
not licensed physicians [24].
The SLD was more appropriately used in prefecture-
level hospitals than in county-level hospitals. A possible
reason for this is that physicians in the prefecture hospi-
tals are typically better trained than those in the county
hospital. The three prefecture-level hospitals were TB
designated hospitals and were also designated for MDR-
TB diagnosis and treatment since 2010. They served as
reference centers for TB diagnosis and treatment for
their respective regions. At least one clinician from the
TB department at the prefecture hospitals received
training provided by the China CDC national experts.
However, with the exception of one county hospital that
was designated for TB care in 2002, the other county
hospitals were designated for TB care between 2011 and
2012, and were not offered training opportunities over
the past years. Instead, they practiced TB services based
on the TB treatment protocols provided in the national
guidelines. Due to this existing situation, the doctors
from prefecture hospitals may have more knowledge
about TB treatment regimens and practice than those
from county hospitals. This may explain why the ration-
ality of FLD was higher in the prefecture hospitals than
in the county hospitals, while the use of SLD was lower
in the prefecture hospitals than in the county hospitals.
Many doctors from the county hospitals did not receive
any training on TB treatments and did not know how to
manage complex cases.
Our study investigated different types of hospitals at
the prefecture and county levels. The medical records
were doubly examined by two experienced physicians. In
addition, we linked the data from the medical records to
the routine surveillance system to assess the rationale of
treatment in different phases for each inpatient. The re-
sults reveal existing problems in TB care that may have
occurred while shifting from CDC model to hospital
model, and should be addressed and solved as soon as
possible. However, there were three limitations to the
study due to time and resource constraints. Firstly, we
did not examine the rationality of TB outpatient treat-
ment regimens. Secondly, we did not analyze the cost of
hospitalization, as irrational treatment regimens may
result in high cost of hospitalization. Thirdly, we did not
evaluate the rationality of treatment regimens for TB
outpatients, nor the use of auxiliary drugs and clinical
examinations, which also play a very important role in
treatment outcome. We will try to cover these limita-
tions in our next study in the three project sites.
Conclusion
The irrational use of anti-TB drugs is a common global
problem, and it is often neglected even though there are
many pressing concerns. The impact of irrational anti-TB
drug use could lead to serious implications, including the
development of MDR-TB [11]. Premature introduction of
SLD for general TB patients may induce more drug-
resistance, which in turn can result in the lack of effective
drugs when general TB patients develop MDR-TB [9]. At
the same time, there is a risk that new drugs will be used
in inappropriate treatment regimens, introducing the sub-
sequent risk of resistance development to these new drugs.
Therefore, the rational use of anti-TB drugs is critically
important for all TB dispensaries. To improve rational
anti-TB drug use, the National Drug Policy should first be
concerned with not only the supply of safe, effective and
appropriate drugs but also with the way in which these
drugs are prescribed and dispensed by health personnel,
which means TB doctors should be well-trained on how
to treat TB patients appropriately. Secondly, the health ad-
ministrative department should develop regulations and
establish supervisory groups to oversee doctors’ behaviors.
Thirdly, the Chinese government should increase direct
investments to the designated hospitals to avoid profit-
seeking behavior. Government funding and supervision
are key factors for the successful operation of designated
TB hospitals [23, 25]. In addition, doctors’ incomes should
not be incentivized by prescribing irrational drugs. Rather,
the funding and focus should be placed on following ap-
propriate treatment regimens and should be related to
health outcomes. Last but not least, the national TB con-
trol program should update the guidelines and hold train-
ing courses to instruct and guide doctors on proper TB
drug regimens.
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